AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form...
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday ...